What are psychedelic substances? Why are they currently being researched in the medical field? Are psychedelics already available for treatment in Europe? These are some of the issues addressed in a new set of EUDA Frequently Asked Questions (FAQs): therapeutic use of psychedelic substances released today.
The FAQs are published in response to the growing interest in the therapeutic use of psychedelic substances and the need for reliable information on the topic. The digital resource is based on the findings from an EUDA project to develop a better understanding of key developments in this…
Read more
Eliminating viral hepatitis as a public health threat by 2030 is a target set under the UN Sustainable Development Goal on Health (SDG 3.3) (1). Ahead of World Hepatitis Day on 28 July, the EUDA has released today an update of its interactive elimination barometer designed to support countries in monitoring their progress towards the elimination of viral hepatitis among people who inject drugs.
Hepatitis C virus (HCV) infection is the infectious disease associated with the highest burden of disease among people who inject drugs (PWID), the virus being easily transmitted through the…
Read more
This week, a delegation from the newly established European Union Drugs Agency (EUDA) visited Washington DC for a series of high-level meetings with US partners. Led by EUDA Executive Director Alexis Goosdeel, the delegation aimed to present the agency's new mandate and discuss potential areas of cooperation within its new responsibilities. This was the first EUDA visit to the US and took place just one week after the official inauguration of the agency in Lisbon. Following a meeting at the EU Delegation to the United States, the visiting EUDA staff members met with the following entities:…
Read more
